Fig. 3: Treatment of multiple melanoma PDXs with vemurafenib, cobimetinib and vemurafenib + cobimetinib. | British Journal of Cancer

Fig. 3: Treatment of multiple melanoma PDXs with vemurafenib, cobimetinib and vemurafenib + cobimetinib.

From: Drug responses are conserved across patient-derived xenograft models of melanoma leading to identification of novel drug combination therapies

Fig. 3

Tumours from MM358X1, MM337X1, MM321X1, MM302X, MM313X, MM314X, MM334X and MM325X were generated in NSG mice (2–4 per group) by subcutaneous injection of 0.5 × 106 cells. Animals with established tumours (average volume of 100 mm3) were randomised and treated with i.p. injections of vehicle, vemurafenib (20 mg/kg), cobimetinib (5 mg/kg) or the combination of vemurafenib (20 mg/kg) + cobimetinib (5 mg/kg) daily 5 days a week for an average of 3 weeks. Tumour volume (mm3) was calculated, and data were expressed as percent change in tumour volume. Error bars are SEM.

Back to article page